In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

Carlos A. Ramos, Rayne Rouce, Catherine S. Robertson, Amy Reyna, Neeharika Narala, Gayatri Vyas, Birju Mehta, Huimin Zhang, Olga Dakhova, George Carrum, Rammurti T. Kamble, Adrian P. Gee, Zhuyong Mei, Meng Fen Wu, Hao Liu, Bambi Grilley, Cliona M. Rooney, Helen E. Heslop, Malcolm K. Brenner, Barbara Savoldo & 1 others Gianpietro Dotti

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have superior activity to others. Because CD28 and 4-1BB signaling activate different pathways, combining them in a single third-generation (3G) CAR may overcome the limitations of each individual costimulatory domain. We designed a clinical trial in which two autologous CD19-specific CAR-transduced T cell products (CD19.CARTs), 2G (with CD28 only) and 3G (CD28 and 4-1BB), were infused simultaneously in 16 patients with relapsed or refractory non-Hodgkin's lymphoma. 3G CD19.CARTs had superior expansion and longer persistence than 2G CD19.CARTs. This difference was most striking in the five patients with low disease burden and few circulating normal B cells, in whom 2G CD19.CARTs had limited expansion and persistence and correspondingly reduced area under the curve. Of the 11 patients with measurable disease, three achieved complete responses and three had partial responses. Cytokine release syndrome occurred in six patients but was mild, and no patient required anti-IL-6 therapy. Hence, 3G CD19.CARTs combining 4-1BB with CD28 produce superior CART expansion and may be of particular value when treating low disease burden in patients whose normal B cells are depleted by prior therapy. CD19.CAR-T cells are highly active against B cell malignancies, but the optimal CAR structure is controversial. Ramos et al. show that combining 4-1BB and CD28 endodomains produces superior CD19-CAR-T cell expansion and persistence compared to CD28 alone and that these cells are clinically effective and safe in aggressive lymphomas.

Original languageEnglish (US)
Pages (from-to)2727-2737
Number of pages11
JournalMolecular Therapy
Volume26
Issue number12
DOIs
StatePublished - Dec 5 2018
Externally publishedYes

Fingerprint

B-Cell Lymphoma
Antigen Receptors
Non-Hodgkin's Lymphoma
T-Lymphocytes
B-Lymphocytes
CD19 Antigens
T-Cell Antigen Receptor
Area Under Curve
CD19-specific chimeric antigen receptor
Interleukin-6
Lymphoma
Neoplasms
Clinical Trials
Cytokines
Therapeutics

Keywords

  • CAR-T cells
  • CD19
  • chimeric antigen receptor
  • immunotherapy
  • second-generation CAR
  • third-generation CAR

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Ramos, C. A., Rouce, R., Robertson, C. S., Reyna, A., Narala, N., Vyas, G., ... Dotti, G. (2018). In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. Molecular Therapy, 26(12), 2727-2737. https://doi.org/10.1016/j.ymthe.2018.09.009

In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. / Ramos, Carlos A.; Rouce, Rayne; Robertson, Catherine S.; Reyna, Amy; Narala, Neeharika; Vyas, Gayatri; Mehta, Birju; Zhang, Huimin; Dakhova, Olga; Carrum, George; Kamble, Rammurti T.; Gee, Adrian P.; Mei, Zhuyong; Wu, Meng Fen; Liu, Hao; Grilley, Bambi; Rooney, Cliona M.; Heslop, Helen E.; Brenner, Malcolm K.; Savoldo, Barbara; Dotti, Gianpietro.

In: Molecular Therapy, Vol. 26, No. 12, 05.12.2018, p. 2727-2737.

Research output: Contribution to journalArticle

Ramos, CA, Rouce, R, Robertson, CS, Reyna, A, Narala, N, Vyas, G, Mehta, B, Zhang, H, Dakhova, O, Carrum, G, Kamble, RT, Gee, AP, Mei, Z, Wu, MF, Liu, H, Grilley, B, Rooney, CM, Heslop, HE, Brenner, MK, Savoldo, B & Dotti, G 2018, 'In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas', Molecular Therapy, vol. 26, no. 12, pp. 2727-2737. https://doi.org/10.1016/j.ymthe.2018.09.009
Ramos, Carlos A. ; Rouce, Rayne ; Robertson, Catherine S. ; Reyna, Amy ; Narala, Neeharika ; Vyas, Gayatri ; Mehta, Birju ; Zhang, Huimin ; Dakhova, Olga ; Carrum, George ; Kamble, Rammurti T. ; Gee, Adrian P. ; Mei, Zhuyong ; Wu, Meng Fen ; Liu, Hao ; Grilley, Bambi ; Rooney, Cliona M. ; Heslop, Helen E. ; Brenner, Malcolm K. ; Savoldo, Barbara ; Dotti, Gianpietro. / In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas. In: Molecular Therapy. 2018 ; Vol. 26, No. 12. pp. 2727-2737.
@article{0d13d5a5066f42e0a1750d96c5011eaf,
title = "In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas",
abstract = "Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have superior activity to others. Because CD28 and 4-1BB signaling activate different pathways, combining them in a single third-generation (3G) CAR may overcome the limitations of each individual costimulatory domain. We designed a clinical trial in which two autologous CD19-specific CAR-transduced T cell products (CD19.CARTs), 2G (with CD28 only) and 3G (CD28 and 4-1BB), were infused simultaneously in 16 patients with relapsed or refractory non-Hodgkin's lymphoma. 3G CD19.CARTs had superior expansion and longer persistence than 2G CD19.CARTs. This difference was most striking in the five patients with low disease burden and few circulating normal B cells, in whom 2G CD19.CARTs had limited expansion and persistence and correspondingly reduced area under the curve. Of the 11 patients with measurable disease, three achieved complete responses and three had partial responses. Cytokine release syndrome occurred in six patients but was mild, and no patient required anti-IL-6 therapy. Hence, 3G CD19.CARTs combining 4-1BB with CD28 produce superior CART expansion and may be of particular value when treating low disease burden in patients whose normal B cells are depleted by prior therapy. CD19.CAR-T cells are highly active against B cell malignancies, but the optimal CAR structure is controversial. Ramos et al. show that combining 4-1BB and CD28 endodomains produces superior CD19-CAR-T cell expansion and persistence compared to CD28 alone and that these cells are clinically effective and safe in aggressive lymphomas.",
keywords = "CAR-T cells, CD19, chimeric antigen receptor, immunotherapy, second-generation CAR, third-generation CAR",
author = "Ramos, {Carlos A.} and Rayne Rouce and Robertson, {Catherine S.} and Amy Reyna and Neeharika Narala and Gayatri Vyas and Birju Mehta and Huimin Zhang and Olga Dakhova and George Carrum and Kamble, {Rammurti T.} and Gee, {Adrian P.} and Zhuyong Mei and Wu, {Meng Fen} and Hao Liu and Bambi Grilley and Rooney, {Cliona M.} and Heslop, {Helen E.} and Brenner, {Malcolm K.} and Barbara Savoldo and Gianpietro Dotti",
year = "2018",
month = "12",
day = "5",
doi = "10.1016/j.ymthe.2018.09.009",
language = "English (US)",
volume = "26",
pages = "2727--2737",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas

AU - Ramos, Carlos A.

AU - Rouce, Rayne

AU - Robertson, Catherine S.

AU - Reyna, Amy

AU - Narala, Neeharika

AU - Vyas, Gayatri

AU - Mehta, Birju

AU - Zhang, Huimin

AU - Dakhova, Olga

AU - Carrum, George

AU - Kamble, Rammurti T.

AU - Gee, Adrian P.

AU - Mei, Zhuyong

AU - Wu, Meng Fen

AU - Liu, Hao

AU - Grilley, Bambi

AU - Rooney, Cliona M.

AU - Heslop, Helen E.

AU - Brenner, Malcolm K.

AU - Savoldo, Barbara

AU - Dotti, Gianpietro

PY - 2018/12/5

Y1 - 2018/12/5

N2 - Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have superior activity to others. Because CD28 and 4-1BB signaling activate different pathways, combining them in a single third-generation (3G) CAR may overcome the limitations of each individual costimulatory domain. We designed a clinical trial in which two autologous CD19-specific CAR-transduced T cell products (CD19.CARTs), 2G (with CD28 only) and 3G (CD28 and 4-1BB), were infused simultaneously in 16 patients with relapsed or refractory non-Hodgkin's lymphoma. 3G CD19.CARTs had superior expansion and longer persistence than 2G CD19.CARTs. This difference was most striking in the five patients with low disease burden and few circulating normal B cells, in whom 2G CD19.CARTs had limited expansion and persistence and correspondingly reduced area under the curve. Of the 11 patients with measurable disease, three achieved complete responses and three had partial responses. Cytokine release syndrome occurred in six patients but was mild, and no patient required anti-IL-6 therapy. Hence, 3G CD19.CARTs combining 4-1BB with CD28 produce superior CART expansion and may be of particular value when treating low disease burden in patients whose normal B cells are depleted by prior therapy. CD19.CAR-T cells are highly active against B cell malignancies, but the optimal CAR structure is controversial. Ramos et al. show that combining 4-1BB and CD28 endodomains produces superior CD19-CAR-T cell expansion and persistence compared to CD28 alone and that these cells are clinically effective and safe in aggressive lymphomas.

AB - Second-generation (2G) chimeric antigen receptors (CARs) targeting CD19 are highly active against B cell malignancies, but it is unknown whether any of the costimulatory domains incorporated in the CAR have superior activity to others. Because CD28 and 4-1BB signaling activate different pathways, combining them in a single third-generation (3G) CAR may overcome the limitations of each individual costimulatory domain. We designed a clinical trial in which two autologous CD19-specific CAR-transduced T cell products (CD19.CARTs), 2G (with CD28 only) and 3G (CD28 and 4-1BB), were infused simultaneously in 16 patients with relapsed or refractory non-Hodgkin's lymphoma. 3G CD19.CARTs had superior expansion and longer persistence than 2G CD19.CARTs. This difference was most striking in the five patients with low disease burden and few circulating normal B cells, in whom 2G CD19.CARTs had limited expansion and persistence and correspondingly reduced area under the curve. Of the 11 patients with measurable disease, three achieved complete responses and three had partial responses. Cytokine release syndrome occurred in six patients but was mild, and no patient required anti-IL-6 therapy. Hence, 3G CD19.CARTs combining 4-1BB with CD28 produce superior CART expansion and may be of particular value when treating low disease burden in patients whose normal B cells are depleted by prior therapy. CD19.CAR-T cells are highly active against B cell malignancies, but the optimal CAR structure is controversial. Ramos et al. show that combining 4-1BB and CD28 endodomains produces superior CD19-CAR-T cell expansion and persistence compared to CD28 alone and that these cells are clinically effective and safe in aggressive lymphomas.

KW - CAR-T cells

KW - CD19

KW - chimeric antigen receptor

KW - immunotherapy

KW - second-generation CAR

KW - third-generation CAR

UR - http://www.scopus.com/inward/record.url?scp=85054452724&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054452724&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2018.09.009

DO - 10.1016/j.ymthe.2018.09.009

M3 - Article

VL - 26

SP - 2727

EP - 2737

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 12

ER -